$PLRX
Pliant Therapeutics Inc
PRICE
$5.27 ▲6.694%
Last Close
VOLUME
210,985
DAY RANGE
4.825 - 5.34
52 WEEK
3.97 - 33.95
Key Metrics
Market Cap
190.25 M
Beta
1.25
Avg. Volume
248.56 K
Shares Outstanding
36.17 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-08
Next Dividend Date
Company Information
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
CEO: Bernard Coulie
Website: pliantrx.com
HQ: 260 Littlefield Avenue South San Francisco, 94080 California
Related News